一个稳定的广泛保护性亚单元疫苗平台对SARS-CoV-2变种的有效性令人担忧
Ravendra Garg1, Qiang Liu2, Jill Van Kessel1
1Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Vaccine
|May 20, 2024
概括
一个新的子单位疫苗平台有效地训练免疫系统对抗SARS-CoV-2变种. 这种可适应的疫苗显示出广泛的保护和稳定性,为未来的冠状病毒威胁提供了希望.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
背景情况:
- 由于SARS-CoV-2的不断演变,因此需要适应性的疫苗平台.
- 现有的疫苗需要经常更新,以应对新出现的关注变种 (VOC).
研究的目的:
- 开发一个"火车模型"子单位疫苗平台,以快速适应SARS-CoV-2变种.
- 评估这个平台对多种VOC的免疫性和保护效果.
主要方法:
- 开发一种"火车模型"疫苗,将SARS-CoV-2武汉S1蛋白与VOCs的受体结合域 (RBDs) 联系起来.
- 使用水乳液中的烯 (SWE) 辅助剂 (Sepivac SWETM) 的配方.
- 叙利亚仓鼠的免疫接种和随后的SARS-CoV-2 VOCs (Omicron BA.1,Delta,Beta) 的挑战.
主要成果:
- 候选疫苗在叙利亚仓鼠中表现出免疫性.
- 观察到对同源和一些异源SARS-CoV-2 VOCs的保护.
- 疫苗配方在2-8°C下表现出长达13个月的稳定性.
结论:
- "火车模型"子单位疫苗平台为开发广泛保护性和适应性疫苗提供了一个有希望的战略.
- 该平台的稳定性和广泛保护的潜力是有利的,特别是对于低资源的设置.
- 这种方法有可能对抗人类和动物当前和未来的贝塔冠状病毒威胁.
更多相关视频
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.6K
00:10Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
7.5K
相关概念视频
Conjugated Proteins
18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Cross-reactivity
31.0K
Overview
31.0K
Vaccinations
44.4K
Overview
44.4K
